These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 36369033)
1. Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside. Liu Y; Wang Y; Sun S; Chen Z; Xiang S; Ding Z; Huang Z; Zhang B Exp Hematol Oncol; 2022 Nov; 11(1):97. PubMed ID: 36369033 [TBL] [Abstract][Full Text] [Related]
2. Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition. Brown TC; Sankpal NV; Gillanders WE Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34209658 [TBL] [Abstract][Full Text] [Related]
3. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Mohtar MA; Syafruddin SE; Nasir SN; Low TY Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32046162 [TBL] [Abstract][Full Text] [Related]
4. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale. Herreros-Pomares A; Aguilar-Gallardo C; Calabuig-Fariñas S; Sirera R; Jantus-Lewintre E; Camps C Crit Rev Oncol Hematol; 2018 Jun; 126():52-63. PubMed ID: 29759567 [TBL] [Abstract][Full Text] [Related]
5. Regulation of the Function and Expression of EpCAM. Xiao D; Xiong M; Wang X; Lyu M; Sun H; Cui Y; Chen C; Jiang Z; Sun F Biomedicines; 2024 May; 12(5):. PubMed ID: 38791091 [TBL] [Abstract][Full Text] [Related]
6. Clinical Relevance of a Candidate Stem Cell Marker, p75 Neurotrophin Receptor (p75NTR) Expression in Circulating Tumor Cells. Okumura T; Yamaguchi T; Watanabe T; Nagata T; Shimada Y Adv Exp Med Biol; 2017; 994():247-254. PubMed ID: 28560678 [TBL] [Abstract][Full Text] [Related]
7. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. Varillas JI; Zhang J; Chen K; Barnes II; Liu C; George TJ; Fan ZH Theranostics; 2019; 9(5):1417-1425. PubMed ID: 30867841 [No Abstract] [Full Text] [Related]
8. Biology and clinical relevance of EpCAM. Keller L; Werner S; Pantel K Cell Stress; 2019 May; 3(6):165-180. PubMed ID: 31225512 [TBL] [Abstract][Full Text] [Related]
9. Shedding light on the EpCAM: An overview. Yahyazadeh Mashhadi SM; Kazemimanesh M; Arashkia A; Azadmanesh K; Meshkat Z; Golichenari B; Sahebkar A J Cell Physiol; 2019 Aug; 234(8):12569-12580. PubMed ID: 30628064 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells isolation: the "post-EpCAM era". Raimondi C; Nicolazzo C; Gradilone A Chin J Cancer Res; 2015 Oct; 27(5):461-70. PubMed ID: 26543332 [TBL] [Abstract][Full Text] [Related]
11. Selective isolation of magnetic nanoparticle-mediated heterogeneity subpopulation of circulating tumor cells using magnetic gradient based microfluidic system. Kwak B; Lee J; Lee D; Lee K; Kwon O; Kang S; Kim Y Biosens Bioelectron; 2017 Feb; 88():153-158. PubMed ID: 27503409 [TBL] [Abstract][Full Text] [Related]
12. Improved detection by ensemble-decision aliquot ranking of circulating tumor cells with low numbers of a targeted surface antigen. Johnson ES; Anand RK; Chiu DT Anal Chem; 2015 Sep; 87(18):9389-95. PubMed ID: 26302174 [TBL] [Abstract][Full Text] [Related]
13. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Song Y; Zhu Z; An Y; Zhang W; Zhang H; Liu D; Yu C; Duan W; Yang CJ Anal Chem; 2013 Apr; 85(8):4141-9. PubMed ID: 23480100 [TBL] [Abstract][Full Text] [Related]
14. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Patriarca C; Macchi RM; Marschner AK; Mellstedt H Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002 [TBL] [Abstract][Full Text] [Related]
15. Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Lin PP Clin Transl Med; 2015 Dec; 4(1):38. PubMed ID: 26718583 [TBL] [Abstract][Full Text] [Related]
16. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015 [TBL] [Abstract][Full Text] [Related]
17. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Driemel C; Kremling H; Schumacher S; Will D; Wolters J; Lindenlauf N; Mack B; Baldus SA; Hoya V; Pietsch JM; Panagiotidou P; Raba K; Vay C; Vallböhmer D; Harréus U; Knoefel WT; Stoecklein NH; Gires O Oncogene; 2014 Oct; 33(41):4904-15. PubMed ID: 24141784 [TBL] [Abstract][Full Text] [Related]
18. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907 [TBL] [Abstract][Full Text] [Related]
19. Enhanced tumor cell isolation by a biomimetic combination of E-selectin and anti-EpCAM: implications for the effective separation of circulating tumor cells (CTCs). Myung JH; Launiere CA; Eddington DT; Hong S Langmuir; 2010 Jun; 26(11):8589-96. PubMed ID: 20155985 [TBL] [Abstract][Full Text] [Related]
20. Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. Lampignano R; Schneck H; Neumann M; Fehm T; Neubauer H Adv Exp Med Biol; 2017; 994():181-203. PubMed ID: 28560675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]